The secretion of growth factors in the tumour microenvironment, such as vascular endothelial growth factor (VEGF) and transforming growth factor-β (TGF-β), can impede the immune response, thereby inhibiting the effect of immunotherapy (11, 12). This evidence concerns the gene VEGFA and neoplasm.